Personalis to Announce Second Quarter 2025 Financial Results
Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website.
About Personalis, Inc.
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).
View source version on businesswire.com: https://www.businesswire.com/news/home/20250722377799/en/
Contacts
Investors:
Caroline Corner
investors@personalis.com
415-202-5678
Media:
pr@personalis.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Celcuity (CELC) Skyrockets 167% on Breast Cancer Treatment Trial
We recently published . Celcuity Inc. (NASDAQ:CELC) is one of the best-performing stocks on Monday. Celcuity soared by 167 percent on Monday to close at $36.79 apiece as investors cheered positive results in its clinical trial for its breast cancer treatment candidate. In a statement on Monday, Celcuity Inc. (NASDAQ:CELC) said it achieved positive topline results from the phase 3 clinical study of gedatolisib combined with palbociclib and fulvestrant—an experimental treatment for adults with two kinds of breast cancer. Called the gedatolisib triple, the three-drug combination reduced risk progression and death by 76 percent as compared with taking fulvestrant alone. Meanwhile, its gedatolisib double, which combines gedatolisib and fulvestrant, lowered the risk of progression and death by 67 percent, also achieving primary endpoints. Celcuity Inc.'s (NASDAQ:CELC) clinical trial success bolsters its chances of filing an approval with the Food and Drug Administration by the fourth quarter of the year. Copyright: bialasiewicz / 123RF Stock Photo Following the results, Celcuity Inc. (NASDAQ:CELC) earned a whopping $60 price target from Leerink, a marked increase from the $28 target previously. It also maintained an 'outperform' rating on its stock. While we acknowledge the potential of CELC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
21 minutes ago
- Business Wire
AGC Biologics' Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva's Tetravalent Shigella Vaccine Candidate
SEATTLE & HEIDELBERG, Germany--(BUSINESS WIRE)-- AGC Biologics, your friendly CDMO expert, today announced a development and manufacturing services agreement with specialty vaccine company Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) to supply drug substance for an investigational four-valent Shigella bioconjugate vaccine at the CDMO's Heidelberg facility. Valneva exclusively licensed the vaccine candidate from LimmaTech Biologics AG, which previously worked with AGC Biologics to establish GMP-compliant manufacturing and quality control of the vaccine's complex protein-polysaccharide conjugates for first-in-human studies. The objective of the new partnership with Valneva is to establish phase II supply relying on the ability of AGC Biologics' Heidelberg site to guide complex molecules through clinical stages. Valneva and LimmaTech announced the launch of a Phase 2 infant study in April, and a Phase 2b Human Challenge Study (CHIM) in November 2024. Shigellosis is the second leading cause of fatal diarrheal disease worldwide, strongly contributing to pediatric morbidity and mortality. It is estimated that up to 165 million infections are due to Shigella, of which 62.3 million occur in children younger than five years. Developing an effective vaccine to prevent this deadly disease is a public health imperative for many areas of the world. "Our site's unique ability to handle complex molecules and multi-valent assets can help this potentially life-saving program reach its next clinical milestone," said Dieter Kramer, Senior Vice President and General Manager, AGC Biologics Heidelberg. "We appreciate Valneva entrusting our team of experts with this challenge and are honored to contribute to efforts that aim to prevent millions of deadly infections in the future." AGC Biologics runs multiple cGMP microbial fermentation lines at its Heidelberg facility. The site has produced biologics products for 40 years. It offers developers freedom-to-operate strain development, proven experience with different bacterial and yeast systems, proprietary plasmid DNA (pDNA) and messenger RNA (mRNA) platforms, large-scale tanks for late-phase protein refolding, the ability to take on early-phase and fast track projects, and late-phase and commercial expertise. To learn more about the microbial system-based biologics, pDNA and mRNA manufacturing site in Heidelberg, visit For more information on AGC Biologics' global CDMO services across all modalities, go to About AGC Biologics AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. We currently employ more than 2,600 Team Members worldwide. AGC Biologics is a part of AGC Inc.'s Life Science Business. The Life Science Business runs 10+ facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit
Forbes
22 minutes ago
- Forbes
Buy Or Sell SOFI Stock At $24?
CHONGQING, CHINA - JULY 27: In this photo illustration, a smartphone displays the logo of SoFi ... More Technologies Inc. (NASDAQ: SOFI), a U.S.-based online personal finance company and digital bank, in front of a screen showing the company's latest stock market chart on July 27, 2025 in Chongqing, China. (Photo illustration by) SoFi Technologies stock (NASDAQ:SOFI) surged 14% in early trading on Tuesday, July 29, after the announcement of strong Q2 earnings. The firm disclosed earnings of $0.08 per share on revenue of $855 million, considerably surpassing Wall Street's projections of $0.06 per share and $804 million, respectively. To add to the positive developments, SoFi has upgraded its full-year 2025 forecast. Management now expects adjusted net revenue of roughly $3.375 billion, indicating approximately 30% annual growth (up from the earlier guidance of 24% to 27%). Furthermore, GAAP EPS is anticipated to be around $0.31 per share, an increase from the previous estimate of $0.27 to $0.28 per share. In fact, in our prior analysis, we noted SoFi's historical tendency to yield positive stock returns following earnings announcements. Nevertheless, the critical question now is whether the stock is worth buying at its current price of $24. We contend that SOFI stock seems risky due to its exceptionally high current valuation. This conclusion is derived from a comparison of SoFi's prevailing valuation against its recent operational performance and its current and historical financial health. Our comprehensive evaluation of SoFi Technologies, which includes key parameters like Growth, Profitability, Financial Stability, and Downturn Resilience, suggests that the company possesses a moderate overall operating performance and financial condition. However, for investors seeking lower volatility than individual stocks, the Trefis High Quality portfolio offers an alternative—having outperformed the S&P 500 and achieved returns exceeding 91% since its inception. Separately, see – Celcuity: What's Happening With CELC Stock? How Does SoFi Technologies' Valuation Compare to The S&P 500? Based on what you pay for each dollar of sales or profit, SOFI stock seems overpriced in comparison to the overall market. How Have SoFi Technologies' Revenues Changed in Recent Years? SoFi Technologies' Revenues have increased significantly over recent years. What is the Profitability of SoFi Technologies? SoFi Technologies' profit margins are roughly at the median level for companies within the Trefis coverage universe. How Resilient is SOFI Stock During Economic Downturns? SOFI stock has performed significantly worse than the benchmark S&P 500 index during some recent downturns. As investors hope for a soft landing of the U.S. economy, how severe could the situation become if another recession occurs? Our dashboard How Low Can Stocks Go During A Market Crash tracks how key stocks performed during and after the last six market crashes. Putting All The Pieces Together: Implications for SOFI Stock In conclusion, SoFi Technologies' performance across the aforementioned parameters is as follows: While SoFi has demonstrated moderate performance in the aforementioned areas, its current valuation represents a considerable risk, rendering it a less appealing investment in our opinion. We recognize that our evaluation may be conservative, and investors might consider paying a premium for SoFi due to its strong revenue growth. (We have explored a possible upside scenario for SoFi in a separate analysis.) Nevertheless, SoFi stock is presently trading at over 9 times its trailing revenues, which is significantly higher than its three-year average of 4.5 times. Additionally, the stock has experienced substantial declines during adverse market conditions. This historical volatility, combined with its inflated valuation, indicates a high level of risk for SoFi at its current price points. Overall, investing in a single stock can be hazardous. Conversely, the Trefis High Quality (HQ) Portfolio, which includes a collection of 30 stocks, has a proven history of comfortably outperforming the S&P 500over the last 4-year period. What accounts for this? As a group, HQ Portfolio stocks have provided better returns with less risk compared to the benchmark index; a smoother ride, as demonstrated in HQ Portfolio performance metrics.
